Research map: Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors

Back to the article

Papers in this map

  1. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations · Alexander Nast · 2020 · 420 citations · Cited by this paper
  2. Dermatophytic Infections of the Eyebrows due to Nannizzia Gypsea: a case series · 2026 · Related
  3. Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States · April Wang Armstrong · 2013 · 392 citations · Cited by this paper
  4. Demodex Folliculitis Following Anifrolumab Infusion · 2026 · Related
  5. French guidelines on the use of systemic treatments for moderate‐to‐severe psoriasis in adults · Florent Amatore · 2019 · 230 citations · Cited by this paper
  6. Evaluation of Fibromyalgia Frequency in Chronic Spontaneous Urticaria Patients Referred to a Tertiary Dermatology Outpatient Clinic · 2026 · Related
  7. Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities · Alan Menter · 2021 · 121 citations · Cited by this paper
  8. A Rare Case of Naegeli–Franceschetti–Jadassohn Syndrome: Clinical and Diagnostic Insights · 2026 · Related
  9. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment · Kim Alexander Papp · 2014 · 116 citations · Cited by this paper
  10. Retrospective Review of Suspected Melanoma Diagnoses Made by a Single-Centre Teledermoscopy Service in New Zealand · 2026 · Related
  11. Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study · Kristian Reich · 2019 · 69 citations · Cited by this paper
  12. Dupilumab in Epidermolysis Bullosa Pruriginosa: “All That Glisters Is Not Gold for Every Age” · 2026 · Related
  13. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis · Paolo GISONDI · 2022 · 67 citations · Cited by this paper
  14. Clinical Outcomes in a Longitudinal Virtual Dermatology Care Model for Eczema and Psoriasis · 2026 · Related
  15. Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR) · Andrew Blauvelt · 2017 · 66 citations · Cited by this paper
  16. Dermoscopic Hallmarks Of Lymphomatoid Papulosis: A Case Series Of Five Histopathologically Proven Lesions · 2026 · Related
  17. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis · Sarah E. Thomas · 2024 · 59 citations · Cited by this paper
  18. Sherlock Holmes In Dermatology: Solving Diagnostic Mysteries With Ultraviolet Light · 2026 · Related
  19. Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis · Selma Atalay · 2020 · 54 citations · Cited by this paper
  20. Childhood Rosacea: Clinical, Diagnostic, and Therapeutic Insights into an Underestimated Pediatric Condition · 2026 · Related
  21. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis · Kilian Eyerich · 2024 · 54 citations · Cited by this paper
  22. Biologics for Reducing Cardiovascular Risk in Psoriasis Patients · Hitoshi Terui · 2023 · 37 citations · Cited by this paper
  23. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting · Ofelia Baniandrés · 2015 · 28 citations · Cited by this paper
  24. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study · Lara S. van der Schoot · 2021 · 24 citations · Cited by this paper
  25. Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study · Selma Atalay · 2020 · 20 citations · Cited by this paper
  26. Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice · Semra Atalay · 2021 · 15 citations · Cited by this paper
  27. Is risankizumab as needed administration a good option for patients with plaque psoriasis? · Paolo Gisondi · 2022 · 15 citations · Cited by this paper
  28. Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice · Selma Atalay · 2020 · 14 citations · Cited by this paper
  29. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting · Esteban Daudén · 2024 · 12 citations · Cited by this paper
  30. Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis · Michael Benzaquen · 2022 · 11 citations · Cited by this paper
  31. The Diagnostic–Therapeutic Care Pathway in Psoriasis: Towards ISO 9001:2015 Certification · Federica Veronese · 2020 · 6 citations · Cited by this paper
  32. Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits · Edoardo Cammarata · 2025 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)